Publications

Filter Publications By:

Danoprevir / Hepatitis C

06/05/2013

Journal of Medicinal Chemistry

Discovery of Danoprevir (ITMN-191/R7227), a Highly Selective and Potent Inhibitor of Hepatitis C Virus (HCV) NS3/4A Protease

Y. Jiang, et al.

Encorafenib / Cancer

06/03/2013

American Society of Clinical Oncology Annual Meeting

Preliminary Results From a Phase Ib/II, Open-Label, Dose-Escalation Study of the Oral Selective BRAF Inhibitor LGX818 in Combination With the Oral MEK1/2 Inhibitor MEK162 in BRAF V600–Dependent Advanced Solid Tumors

R. Kefford, et al.

Encorafenib / Cancer

06/03/2013

American Society of Clinical Oncology Annual Meeting

Preliminary Results From a Phase Ib/II, Open-Label, Dose-Escalation Study of the Oral Selective BRAF Inhibitor LGX818 in Combination With the Oral MEK1/2 Inhibitor MEK162 in BRAF V600–Dependent Advanced Solid Tumors

R. Kefford, et al.

Selumetinib / Cancer

06/01/2013

American Society of Clinical Oncology Annual Meeting

Phase II Study of Selumetinib vs Temozolomide in Patients with Advanced Uveal Melanoma (CTEP #8443)

R. D. Carvajal

ARRY-502 / Asthma

05/13/2013

American Thoracic Society International Conference

Th2 Signature Selection Strategies for CRTh2 Antagonists: Baseline Characteristics of a Mild to Moderate Persistent Asthma Population

D. Chantry, et al.

ARRY-614 / MDS

04/06/2013

American Association for Cancer Research Annual Meeting

The Design and Early Development of the P38/Tie-2 inhibitor, ARRY-614 in Hematologic Cancers

K. Koch Ph.D.

Filanesib / Multiple Myeloma

04/04/2013

International Myeloma Workshop

Single-Agent Activity of the Novel KSP Inhibitor ARRY-520 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Results from Subgroup Analyses

S. Lonial, M.D. et al.

Filanesib / Multiple Myeloma

04/04/2013

International Myeloma Workshop

A Phase 1 Study of ARRY-520 with Bortezomib in Relapsed or Refractory Multiple Myeloma

A. Chari, M.D., et al.

Binimetinib / Cancer

02/13/2013

The Lancet Oncology

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

P. A. Ascierto, et al.

Selumetinib / Cancer

12/21/2012

The Lancet Oncology

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

J. Farley, et al.